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INTRODUCTION
Allergic rhinitis (AR) and asthma are both allergic diseases of 
the upper and lower airways that appear to have similar patho-
physiologic features.
1,2 Common characteristics of these diseas-
es include variable degrees of airflow obstruction, airway hyper-
responsiveness, and inflammation in response to allergens. In 
addition, chronic inflammatory reactions caused by allergens 
induce significant changes in the structural components of the 
airway wall, collectively known as remodeling.
Airway remodeling is a central feature of asthma, and it has 
been demonstrated by a number of studies.
3-5 However, there 
has been much debate about whether such remodeling occurs 
in AR. Recent studies have revealed that airway remodeling can 
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occur in the nasal mucosa, even though the pathologic extent 
of nasal remodeling might differ from that of the bronchus.
6,7
Airway remodeling results in structural changes that include 
smooth muscle hypertrophy, goblet cell hyperplasia, subepi-
thelial fibrosis, inflammatory cell infiltration, and increased 
vascularity.
8 Despite the fact that increased vascularity – also 
called vascular remodeling – is a crucial step in the pathogene-
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Purpose:  There is growing evidence that nasal airway remodeling occurs in allergic rhinitis (AR). Although angiogenesis is an important compo-
nent of airway remodeling in asthma, its involvement in AR has been little studied. Furthermore, information regarding the role of potent angiogenic 
factors, such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), in the nasal airway remodeling process is limit-
ed. This study was conducted to investigate the role of VEGF and PDGF in nasal airway remodeling, and to assess the preventive effects of anti-an-
giogenic drugs on this process in a murine AR model.  Methods:  Mice were systemically sensitized and subjected to inhalation of ovalbumin (OVA) 
twice a week for 3 months. Control mice were challenged with phosphate buffered saline, while the treatment group received SU1498, a VEGF re-
ceptor inhibitor, and/or AG1296, a PDGF receptor inhibitor, via intraperitoneal injection 4 hours prior to each OVA inhalation. Staining using hematox-
ylin and eosin, Masson’s trichrome, and periodic acid-Schiff were separately performed to assess eosinophil infiltration, subepithelial fibrosis, and 
goblet cell hyperplasia, respectively, in the nasal airway. Immunohistochemical staining for matrix metalloproteinase-9 (MMP-9) and tissue inhibitor 
of metalloproteinase-1 (TIMP-1) was also conducted.  Results:  Repetitive intranasal inhalation of OVA resulted in significant increases in eosino-
phil infiltration, subepithelial fibrosis, goblet cell count, and MMP-9/TIMP-1 expression. Administration of SU1498 or AG1296 prevented these ab-
normal responses.  Conclusions:  The results of this study suggest that a causal relationship may exist between angiogenic factors and nasal air-
way remodeling in AR. Inhibition of VEGF or PDGF receptors may, in turn, suppress the remodeling process through the regulation of MMP-9/TIMP-1 
expression.
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sis of the airway remodeling process in asthma,
9 it has been 
largely overlooked in studies of AR. Histological examinations 
have revealed a significant increase in the number of microves-
sels in the airways of both pediatric and adult asthma patients.
10,11 
Vascular remodeling has also been demonstrated in a rat mod-
el in response to chronic allergen exposure.
12 In addition, nasal 
vasodilatation and increased vascular permeability are impor-
tant features of AR, although the underlying mechanisms are 
unknown.
Vascular endothelial growth factor (VEGF) and platelet-de-
rived growth factor (PDGF) are potent angiogenic factors that 
also act as proinflammatory cytokines by increasing endotheli-
al cell permeability and promoting the upregulation of endo-
thelial cell adhesion molecules.
13 VEGF plays a key regulatory 
role in the formation of blood vessels by controlling the prolif-
eration and migration of endothelial cells. The action of VEGF 
depends on its interaction with PDGF-B during the stabilizing 
process of vascular walls.
14 Increased expression of VEGF and 
PDGF is a well-documented feature of asthma.
11,15 Of note, VEGF 
is also known to mediate vascular and extravascular remodel-
ing and inflammation in the lung.
16 In addition, administration 
of anti-PDGF neutralizing antibody significantly reduces airway 
wall thickening induced by allergen challenge.
17 Matrix metal-
loproteinases (MMPs) also play important roles in airway re-
modeling caused by VEGF.
18 A close relationship exists between 
VEGF and MMP-9 expression in the sputum of asthma pa-
tients, and inhibition of VEGF receptors downregulates the ex-
pression of MMP-9 in murine models of asthma.
Therefore, it is hypothesized that angiogenic factors, such as 
VEGF and PDGF, and associated MMPs are responsible for na-
sal airway remodeling in AR. However, there have been few 
studies to elucidate their precise functions. This study was con-
ducted to investigate the role of VEGF and PDGF in nasal air-
way remodeling and to assess the preventive effects of anti-an-
giogenic drugs on this process in a murine AR model.
MATERIALS AND METHODS
Animals
Four week-old female BALB/c mice (20-30 g) were used in all 
experiments. The study protocol followed the principles for lab-
oratory animal research, as outlined in the Animal Welfare Act 
and Department of Health, Education, and Welfare guidelines 
for the experimental use of animals (National Institutes of 
Health), and was approved by our institution’s animal subjects 
committee.
Sensitization, anti-angiogenic drug delivery, and allergen 
challenge
Forty-eight mice were divided into the following six groups: 
negative control mice challenged with phosphate-buffered sa-
line (PBS; group A), mice challenged with ovalbumin (OVA, 
Grade V; Sigma, St. Louis, MO, USA; group B), control mice 
treated with dimethyl sulfoxide (DMSO; Sigma) prior to intra-
nasal OVA challenge (group C), mice treated with SU1498 dis-
solved in DMSO prior to intranasal OVA challenge (group D1), 
mice treated with AG1296 dissolved in DMSO prior to intrana-
sal OVA challenge (group D2), and mice treated with both 
SU1498 and AG1296 dissolved in DMSO prior to intranasal OVA 
challenge (group D3). 
The procedure for allergen sensitization and challenge was 
performed as previously described and is summarized in Fig. 1.
6 
Briefly, mice were sensitized on days 0, 7, 14, and 21 by intra-
peritoneal injection with 300 μL PBS alone, or PBS with 25 μg 
OVA plus 1 mg aluminum hydroxide (Sigma). Starting on day 
28, air with 2% aerosolized OVA was administered for 30 min-
utes daily for 7 days using a nebulizer (PulmoAide, Somerset, 
PA, USA). Aerosolized OVA (particle size, 0.5-5.0 μm) was gen-
erated by passing the solution through a closed 8,800 cm
3 (20×
22×20 cm) acrylic chamber. Mice received a single intraperito-
neal injection (9 mg/kg) of SU1498 (#T-2710; Calbiochem, La 
Jolla, CA, USA; group D1), AG1296 (Cayman Chemical, Ann Ar-
bour, MI, USA; group D2), or SU1498 plus AG1296 (group D3) 
dissolved in DMSO 4 hours prior to each aerosolized OVA ex-
posure.
19 Group C received an intraperitoneal injection of 
DSMO alone. Then 24 hours after the final OVA challenge, half 
of the mice were sacrificed (0 month group). The remaining 
mice received the 2% OVA aerosol by inhalation twice a week 
for the next 3 months (3 month group). Group A received PBS 
alone by inhalation. Each mouse was sacrificed 24 hours after 
the final OVA challenge, and their nasal tissues were harvested 
for subsequent analysis. 
Evaluation of allergic responses 
Nasal symptom scores. Prior to sacrifice, mice were subjected 
to intranasal provocation with 200 μg OVA, and the frequency 
of sneezing and nose scratching was monitored for 15 minutes 
Day 0  7  14  21  37  40  44  47  114 117
 Week 1  Week 2  Week 12
0 month  3 month
Fig. 1.  Experimental protocol for mouse sensitization and drug treatment. Mice 
were sensitized by intraperitoneal injection of inhalation of ovalbumin (OVA) 
plus aluminum hydroxide on days 0, 7, 14, and 21. Intranasal challenge was 
performed by daily OVA inhalation on days 28 to 35, followed by drug treat-
ment, and then OVA inhalation was resumed twice a week for the next 3 
months. Control mice were sensitized and challenged with PBS twice a week 
for 3 months. Mice were sacrificed 24 hr after the final OVA challenge. SU1498 
or AG1296 treatment was given intraperitoneally 4 hr before each OVA inhala-
tion. Arrows indicate intraperitoneal injection of OVA plus aluminum hydroxide; 
triangles, intranasal OVA or phosphate-buffered saline challenge; reverse trian-
gles, intraperitoneal SU1498 or AG1296 injection; circles, sacrifice. Angiogenic Factors in Nasal Airway Remodeling 
Allergy Asthma Immunol Res. 2012 January;4(1):37-45.  http://dx.doi.org/10.4168/aair.2012.4.1.37
AAIR 
39 http://e-aair.org
to evaluate early allergic responses. 
Measurement of total IgE and OVA-specific IgE. Serum levels 
of total IgE and OVA-specific IgE were measured by solid-phase 
enzyme-linked immunosorbent assay (ELISA). Serum samples 
were collected 24 hours after the final nasal OVA challenge, and 
10 μg/mL of OVA was used to coat a microtiterplate. Bound im-
munoglobulin isotypes were detected with specific secondary 
antibody (biotin-conjugated rat antimouse IgE mAb was pur-
chased from BD Pharmingen, San Jose, CA). Total serum IgE 
was measured by standard ELISA using antimouse IgE capture 
mAb (BD Pharmingen) and detection antibody was measured 
as described for the OVA-specific IgE ELISA.
Measurement of cytokines in splenocyte culture supernatants. 
Spleens were harvested 24 hours after the final intranasal chal-
lenge. Single-cell suspensions were plated on 96-well plates at a 
final concentration of 5×10
6 cells/well in RPMI-1640 contain-
ing 10% fetal bovine serum and penicillin/streptomycin. The 
cells were stimulated with OVA for 72 hours. Supernatants were 
collected and stored at −70°C until analysis.
IL-4 and TGF-β were measured in OVA-stimulated splenocyte 
culture supernatants using commercially available ELISA kits 
(R&D Systems, Inc., Minneapolis, MN, USA). After measuring 
the optical density at 450 nm, the concentrations of IL-4 and 
TGF-β were calculated by interpolation from a standard curve 
and expressed as ng/mL. 
Histological assessment
Mice were sacrificed 24 hours after the final OVA challenge, 
and nasal tissues were obtained for analysis. Two sections of 
the nasal septum, 4 μm apart, were made 5 mm posterior to the 
nasal vestibule and used for histological assessment.
Eosinophil counts. The nasal septum sections were stained 
with hematoxylin and eosin to assess inflammatory cell infiltra-
tion. Eosinophils were morphologically defined by the presence 
of eosinophilic granules in the cytoplasm and a 2-lobed nucle-
us, and they were counted under a microscope at ×400 magni-
fication. 
Periodic acid-Schiff (PAS) staining for goblet cell hyperplasia. 
PAS staining was performed on the nasal septal mucosa sec-
tions to visualize the development of goblet cell hyperplasia. 
The results are presented as the number of goblet cells per 100 
μm nasal septal mucosa. 
Masson’s trichrome staining. Masson’s trichrome staining was 
used to reveal the subepithelial deposition of collagen in the 
nasal mucosa. Positive trichrome-stained areas were quantified 
using ImageJ software (National Institutes of Health, http://rs-
bweb.nih.gov/ij/) to assess the degree of subepithelial fibrosis. 
Positive-stained areas for each group of mice were reported as 
percentages of positive-stained area/whole area. All slides were 
read by a single pathologist who was blinded to the experimen-
tal conditions.
Immunohistochemistry 
Nasal septal musosa sections were stained immunohisto-
chemically to evaluate the expression of MMP-9 and TIMP-1. 
Endogenous peroxidase activity was blocked with 3% hydrogen 
peroxide in methanol. Nonspecific antigenic sites were blocked 
with 0.3% Triton X-100 plus 10% normal donkey serum in PBS 
at 37°C for 2 hours. Then the sections were incubated overnight 
at 4°C with anti-mouse mAb against MMP-9 or TIMP-1 (R&D 
Systems) at a dilution of 1:50. Isotype controls were also includ-
ed. Next, the sections were incubated in the dark for 1 hours at 
room temperature with an anti-rabbit secondary antibody con-
jugated to AlexaFluor 594 (Invitrogen, Carlsbad, CA, USA) di-
luted in 0.01% Triton X-100 plus 1% normal donkey serum in 
PBS at a final dilution of 1:500. Finally, the sections were coun-
terstained with 5 μg/mL 4’ ,6-diamidino-2-phenylindole (DAPI) 
to stain cell nuclei and imaged using a confocal microscope 
(LSM510 META; Carl Zeiss, Gottingen, Germany). 
Statistical analysis
All quantitative results are expressed as mean±SD. Statistical 
analysis was performed using SPSS 17.0 software (SPSS Inc., 
Chicago, IL, USA), and the Mann-Whitney U test was used for 
mean analysis. 
RESULTS
Effect of anti-angiogenic drug treatment on allergy symptoms 
and production of IgE 
The frequency of nasal rubbing and sneezing by the positive 
control and DMSO control mice at 3 months scored 7.8±1.3 
and 6.8±1.0, respectively, which was significantly higher than 
that of the negative control mice (0.8±1.0, P=0.000). The symp-
tom scores of mice treated with anti-angiogenic drugs (group 
D1=6.0±4.5, group D2=4.8±1.1, and group D3=5.8±1.7) did 
not significantly differ from that of positive control mice at 3 
months (P=0.149). 
All OVA treated mice had significantly higher total IgE, as well 
as OVA-specific IgE, than negative control mice at both 0 and 3 
months (P<0.001). However, no differences were observed, 
comparing groups B, C, D1, and D2 with group D3, in levels of 
total IgE (P=0.861 at 0 months and P=0.605 at 3 months) or OVA-
specific IgE (P=0.489 at 0 months and P=0.093 at 3 months). 
Effect of anti-angiogenic drug treatment on eosinophilic 
inflammation
Eosinophil counts in the nasal mucosa are shown in Fig. 2A. 
At 0 months, eosinophil counts were similar in all OVA-treated 
groups of mice (P=0.512). At 3 months, the mean eosinophil 
counts in groups B and C were 55.5±6.9 and 62.3±12.5, re-
spectively. In the drug-treated mice, eosinophil counts aver-
aged 33.2±5.0 (group D1), 28.2±10.3 (group D2), and 37.6±
11.0 (group D3), which were all significantly reduced compared Moon et al.
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to groups B and C (P<0.001). 
Effect of anti-angiogenic drug treatment on the production of 
inflammatory cytokines 
IL-4 was significantly elevated in OVA-treated mice (groups B, 
C, D1, D2, and D3), compared to the negative control mice 
(group A), as measured in splenocyte culture supernatants at 
both 0 (P<0.001) and 3 (P<0.001) months (Fig. 2B). However, 
neither SU1498 nor AG1296 treatment affected OVA-induced 
IL-4 production by splenocytes (P=0.230 comparing groups B, 
C, D1, D2, and D3 with group A at 0 months and P=0.246 for 
the same comparison at 3 months). There were no significant 
differences in TGF-β production by splenocytes from OVA-
treated versus control mice (P=0.116 at 0 months and P=0.093 
at 3 months) (Fig. 2C). 
Effect of anti-angiogenic drug treatment on nasal airway 
remodeling 
All mice showed minimal subepithelial trichrome staining in 
their nasal septal mucosa at 0 months (Fig. 3A). Areas that 
stained positive for trichrome were markedly increased in the 
OVA-treated mice in groups B and C at 3 months, but were sig-
nificantly less in the OVA-treated mice that also received anti-
angiogenic drugs (groups D1, D2, and D3; P<0.001) (Fig. 3B). A 
quantitative summary of positive-stained areas for each group 
is shown in Fig. 3C. 
Goblet cell hyperplasia
Differences in goblet cell counts are summarized in Fig. 4. At 0 
months, goblet cell numbers were similar in all groups of mice. 
At 3 months, all OVA-treated mice (groups B, C, D1, D2, and 
D3) had significantly more goblet cells than negative control 
mice (group A; P<0.001). No significant differences were found 
between groups B, C, D1, D2, and D3 (P=0.625).
Effect of anti-angiogenic drug treatment on MMP-9 and 
TIMP-1 expression 
At 0 months, MMP-9 and TIMP-1 expression was sparse in the 
nasal mucosa of mice from all groups (Fig. 5A). At 3 months, 
higher MMP-9 and TIMP-1 expression was found in the basal 
and subepithelial layers of nasal tissue. OVA-treated mice 
(groups B and C) had more MMP-9 and TIMP-1 expression 
than PBS-treated mice (group A). Drug-treated mice (groups 
D1, D2, and D3) had lower MMP-9 and TIMP-1 expression 
than OVA-treated (positive control) mice (Fig. 5B). No signifi-
cant differences were found between the various drug treatment 
groups. 
A quantitative assessment of MMP-9 and TIMP-1 expression 
in the nasal septum of the different treatment groups is sum-
marized in Figs. 5C and 6. At 0 months, all groups of mice 
showed similar levels of MMP-9 and TIMP-1 expression. At 3 
months, OVA-treated mice (groups B, C, D1, D2, and D3) had 
significantly higher levels of MMP-9 and TIMP-1 than negative 
control mice (P<0.001). Mice treated with the anti-angiogenic 
drugs (groups D1, D2, and D3) showed significantly lower 
MMP-9 and TIMP-1 expression compared to groups B and C 
(P<0.001 for MMP-1 staining and P<0.001 for TIMP-1 stain-
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Fig. 2.  Inhalation of ovalbumin (OVA) treatment enhances eosinophil recruit-
ment and the production of IL-4 and TGF-β. (A) Eosinophils were counted in na-
sal mucosa sections from mice in groups B, C, D1, D2, and D3 that were sacri-
ficed at 0 or 3 months. (B) IL-4 production was measured in the supernatant of 
OVA-stimulated splenocyte cultures from mice sacrificed at 0 or 3 months. (C) 
TGF-β production was measured in the supernatant of OVA-stimulated spleno-
cyte cultures from mice sacrificed at 0 or 3 months. Data are presented as the 
mean±SD. Group A, phosphate-buffered saline treated; group B, OVA treated; 
group C, dimethyl sulfoxide/OVA treated; group D1, OVA/SU1498 treated; group 
D2, OVA/AG1296 treated; group D3, OVA/SU1498/AG1296 treated. *P<0.05.Angiogenic Factors in Nasal Airway Remodeling 
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ing). The ratio of MMP-9 to TIMP-1 expression was calculated 
for each group of mice at both time points, but no statistically 
significant differences were observed between the groups. 
DISCUSSION
In this study, we showed that OVA challenge of AR mice for 3 
months induced nasal airway remodeling, as demonstrated by 
increased subepithelial fibrosis, goblet cell numbers, and MMP-
9/TIMP-1 expression in the nasal septal mucosa. Importantly, 
these airway-remodeling processes, with the exception of gob-
let cell hyperplasia, were prevented with long-term treatment 
with anti-angiogenic drugs. 
Angiogenesis is a complex and dynamic process that is char-
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Fig. 3.  Anti-angiogenic drug treatment significantly reduces subepithelial fibro-
sis in the nasal septum. Masson’s trichrome staining was performed on nasal 
septum sections of mice at (A) 0 and (B) 3 months. Images were taken at ×200 
magnification. (C) A quantitative summary of areas that stained positive for tri-
chrome. Values are reported as percentages of positive-stained area/whole area 
for each group of mice. Group A, phosphate-buffered saline treated; group B, 
inhalation of ovalbumin (OVA) treated; group C, dimethyl sulfoxide/OVA treat-
ed; group D1, OVA/SU1498 treated; group D2, OVA/AG1296 treated; group D3, 
OVA/SU1498/AG1296 treated.
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Fig. 4.  Anti-angiogenic drug treatment significantly reduces goblet cell hyper-
plasia in the nasal septum. Periodic acid-Schiff (PAS) staining was performed 
on nasal septum sections of mice at (A) 0 and (B) 3 months. Images were taken 
at ×400 magnification. (C) Goblet cell counts are reported as the mean±SD 
for each group of mice. Group A, phosphate-buffered saline treated; group B, 
inhalation of ovalbumin (OVA) treated; group C, dimethyl sulfoxide/OVA treat-
ed; group D1, OVA/SU1498 treated; group D2, OVA/AG1296 treated; group D3, 
OVA/SU1498/AG1296 treated. Moon et al.
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acterized by a coordinated sequence of cellular interactions.
20 
VEGF is known to regulate the proliferation, migration, and 
survival of vascular endothelial cells. In addition to acting as an 
angiogenic factor, VEGF has been identified as a survival factor 
for endothelial cells and newly formed blood vessels.
21 Blood 
vessels undergoing maturation, on the other hand, are not de-
pendent on VEGF.
22 Instead, they are supported by pericytes, 
which provide stability while PDGF mediates their matura-
tion.
22 Consequently, inhibition of multiple angiogenic path-
ways, for example VEGF and PDGF, may be more effective at 
blocking angiogenesis than targeting one particular angiogenic 
factor. Targeting multiple angiogenic signaling pathways by 
polyvalent tyrosine kinase inhibitors has been investigated as a 
promising strategy to interfere with angiogenesis.
20,23 In fact, 
previous reports have documented that the combined inhibi-
tion of VEGF and PDGF signaling effectively inhibits neovascu-
larization.
20,22,23
SU1498 ((E)-3-(3, 5-Diisopropyl-4-hydroxyphenyl)-2-[(3-phe-
nyl-n-propyl) aminocarbonyl] acrylonitrile) is a potent and se-
lective inhibitor of Flk-1 kinase, a VEGF receptor kinase. 
AG1296 (6, 7-Dimethoxy-3-phenylquinoxaline) inhibits PDGF 
receptor kinase, which blocks signaling through human PDGF 
α-receptors and β-receptors. In this study, we investigated the 
effects of SU1498 and AG1296 alone, or in combination, on air-
way remodeling in an AR mouse model. These receptor inhibi-
tors are known to decrease VEGF and PDGF production, re-
spectively, by inhibiting the migration and inflammatory re-
sponses of angiogenic factor-producing cells or blocking the 
autoinductive VEGF or PDGF pathway.
18 
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MMP-9 is a zinc- and calcium-dependent, substrate-specific 
endopeptidase, and is the major proteinase involved in the 
turnover of the extracellular matrix and basement membrane 
proteins in respiratory epithelium. TIMPs are a family of secret-
ed proteins that selectively, but reversibly, inhibit metallopro-
teinases.
24 Therefore, MMP-9 and TIMP-1 are considered to be 
involved in the tissue remodeling process induced by inflam-
mation. The increased expression of MMP-9 and TIMP-1 that 
we detected in the nasal septal mucosa after long-term OVA 
challenge is consistent with previous reports.
25,26 
A positive correlation between VEGF and MMP-9 levels in 
asthmatic patients has been documented.
18 Furthermore, in a 
previous study, VEGF receptor inhibitors were effective at re-
ducing MMP-9 expression, and reversing all pathophysiologic 
signs, in a murine asthma model,
18 consistent with our findings. 
We also determined that infiltrating eosinophils were signifi-
cantly reduced in the AR mice treated with SU1498 or AG1296. 
Eosinophils are the main effector cells of allergic inflammation 
and an important source of VEGF, along with other inflamma-
tory and structural cells in inflamed tissue.
27 Eosinophils also 
produce several other molecules, such as fibroblast growth fac-
tor-2, MMP-9, TIMP-1, IL-13, and IL-17, all of which are impli-
cated in tissue remodeling processes.
28 
One plausible mechanism of nasal airway remodeling is that 
VEGF increases vascular permeability, causing leakage of plas-
ma proteins and inflammatory cells, including eosinophils, into 
the extravascular space. This relocation of eosinophils, or other 
inflammatory cells, may cause the upregulation of MMP-9 and 
TIMP-1. Inhibition of plasma leakage and the subsequent mi-
gration of eosinophils by administering SU1498 and/or AG1296 
may therefore reduce MMP-9 and TIMP-1 production. En-
hanced eosinophilic inflammation in the nasal mucosa of hu-
man AR patients in response to VEGF secretion has been dem-
onstrated.
29 Our data using AR mice suggest that MMP-9 is gen-
erated in response to long-term allergen challenge and may be 
produced by local airway inflammatory cells, likely eosinophils. 
The PDGF family of proteins includes important mitogens 
and chemoattractants for monocytes, and PDGF-B, in particu-
lar, is known to induce a variety of MMPs, including MMP-2 
and MMP-9.
30 A recent study revealed that PDGF facilitates the 
migration of airway smooth muscle cells by modifying the MMP–
TIMP balance via the ERK pathway.
31 PDGF is also an impor-
tant activator of eosinophils in pulmonary inflammation asso-
ciated with asthma.
32
We observed goblet cell hyperplasia after long-term repetitive 
allergen challenge of AR mice. However, administration of anti-
angiogenic drugs did not inhibit the hyperplasia process. Gob-
let cell hyperplasia typically occurs in response to various air-
way insults. Cytokines (e.g., interleukin-4, -9, and -13), bacterial 
products (e.g., lipopolysaccharide and lipoteichoic acid), pro-
teinases (e.g., elastase and cathepsin G), and oxidants from T 
helper-2 (Th2) lymphocytes, bacteria, and neutrophils have all 
been shown to induce goblet cell hyperplasia.
33 Therefore, the 
inhibition of neovascularization and inflammatory cell infiltra-
tion by administration of anti-angiogenic drugs may not be suf-
ficient to suppress the hyperplasia process. For example, the 
production of IL-4 was not affected by the administration of an-
ti-angiogenic drugs in our study. Th2 lymphocyte-derived cyto-
kines, including IL-4, IL-9, and IL-13, are known to be highly ef-
fective in inducing goblet cell hyperplasia.
34 
In this study, neither eosinophil infiltration nor MMP-9/TIMP-
1 expression was enhanced by the combined use of SU1498 
and AG1296, as compared to injecting either drug alone. VEGF 
and PDGF are responsible for the initiation and maturation of 
neovascularization, respectively.
20 If neovascularization itself 
were the leading cause of airway remodeling, synergistic effects 
using both drugs would be expected. Instead, our results sug-
gest that increased vascular permeability followed by eosino-
phil infiltration may explain the increased expression of MMP-
9/TIMP-1. Alternatively, the administrative dose of these drugs 
may have been too low to detect synergistic effects. In addition, 
we injected mice with a single solution containing both VEGF 
and PDGF inhibitors (group D3). We may have seen different 
results if we had administered the inhibitors separately, each in 
a discrete injection site.
Administration of anti-angiogenic drugs partially inhibited 
the expression of MMP-9 and TIMP-1, and also prevented sub-
epithelial fibrosis in this study. MMP-9 and TIMP-1 are synthe-
sized and secreted by connective tissue, comprising fibroblasts, 
endothelial cells, and inflammatory cells (including eosino-
phils).
35 Thus, other sources of MMP-9 and TIMP-1 may have 
compensated for the drug-induced reduction, explaining our 
observation of only partial inhibition. Alternatively, the admin-
istrative dose of the anti-angiogenic drugs we used to reduce 
plasma leakage and migration of inflammatory cells may have 
been too low to completely prevent the remodeling process. 
Further studies analyzing the dose-response relationship will 
help to clarify this discrepancy. 
In summary, the results of this study demonstrate that long-
term and repetitive allergen challenge induces eosinophil infil-
tration, MMP-9/TIMP-1 release, and evidence of airway re-
modeling in the nasal cavity of AR mice. Although anti-angio-
genic drugs (i.e., VEGF and PDGF receptor inhibitors) did not 
influence the early allergic response or inflammation, they 
were able to prevent the airway remodeling process during ex-
posure to a long-term allergen challenge to the nasal airway. 
These results suggest that clinical use of angiogenic inhibitors 
may help treat hypertrophy of the nasal septum or turbinates as 
well as AR.
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